Thursday, December 13, 2007

Pharmacotherapy Considerations in Advanced Cardiac Life Support

Several approaches can be used to manage symptomatic bradycardia.
This includes use of an internal or external model or drug therapy, either by increasing the rate of conduction by stimulating ?1-adrenergic succeeder human action with catechola-mines or by blocking parasympathetic executive department with atropine.Atropine
Atropine inhibits cholinergic responses that diminish courage rate and systemic vascular resis-tance, and is recommended for use in patients with symptomatic bradycardia, PEA with bradycardia, and asystole.
Supporting data are limited and unclear in basis of the dominance of atropine for asystole.
One size prospective power in 21 patients found no significant difference of opinion in the rate of successful resuscitation in patients who received atropine and in those who did not (control group).
A large retrospective profundity psychology in 170 patients with asystole that was resistant to epinephrine found a significantly higher rate of resuscitation associated with atropine (14%) compared with medicament (0%).
The recommended dose of atropine for the social control of asystole or PEA associated with bradycardia is 1 mg intravenously, repeated every 3
This is a part of article Pharmacotherapy Considerations in Advanced Cardiac Life Support Taken from "Atropine Sulfate" Information Blog

No comments: